Rockville biotech Sequella inc. is looking to raise at least $20 million to advance its lead antibiotic candidate through clinical trials in drug-resistant tuberculosis and the stomach bacteria H. pylori.
If there ever was a time for the company to hit the gas pedal, it’s now. The resurgence of tuberculosis, especially in populous nations such as India and Russia, has brought what was thought of as a 19th century disease back into the spotlight. And the rise of multiple-drug-resistant strains of TB has made that fear very real in the mind of the U.S. consumer.
{iframe}http://www.bizjournals.com/washington/print-edition/2013/03/15/maryland-biotech-sequella-on-hunt-for.html?ana=e_ph_prem&u=wjGEy67ABoSnsLErlc5ry0j5hx3{/iframe}